Skip to main content

Table 2 Clinical characteristics of patients across quartiles of AST/ALT ratio

From: AST/ALT ratio as a predictor of mortality and exacerbations of PM/DM-ILD in 1 year—a retrospective cohort study with 522 cases

Characteristic Group 1 (≤ 0.91) Group 2 (0.91–1.26) Group 3 (1.26–1.73) Group 4 (> 1.73) p value
N 133 128 131 130  
Follow-up time (days) 365 (53–365) 365 (80.5–365) 365 (67–365) 224 (35–365) 0.01
Sex, male 58 (43.6) 38 (29.7) 44 (33.6) 27 (20.8) 0.001
Age, years
 ≤ 40 31 (23.3) 20 (15.6) 28 (21.4) 22 (16.9) 0.205
 40–60 85 (63.9) 85 (66.4) 74 (56.5) 78 (60)  
 > 60 17 (12.8) 23 (18) 29 (22.1) 30 (23.1)  
Diagnosis
 DM 82 (61.7) 87 (68) 86 (65.6) 105 (80.8) 0.046
 CADM 16 (12) 12 (9.4) 12 (9.2) 7 (5.4)  
 PM 35 (26.3) 29 (22.7) 33 (25.2) 18 (13.8)  
OLS 11 (8.3) 12 (9.4) 16 (12.2) 11 (8.5) 0.681
Comorbidities
 Diabetes mellitus 8 (6) 11 (8.6) 8 (6.1) 9 (6.9) 0.834
 Hypertension 13 (9.8) 20 (15.6) 11 (8.4) 10 (7.7) 0.144
 Chronic hepatitis B 6 (4.5) 3 (2.3) 7 (5.3) 8 (6.2) 0.5
MDA5+ 18 (13.5) 17 (13.3) 17 (13) 18 (13.8) 0.997
HB 132 (122.5–144.5) 123 (112–132) 120 (111–131) 116.5 (104.5–126) < 0.001
PLT 192 (140.5–233.5) 194.5 (144–262) 195 (154–261) 196 (134.25–264.25) 0.714
WBC 8.07 (6.2–10.63) 6.92 (4.68–10.52) 5.89 (4.49–8.05) 5.41 (3.97–7.81) < 0.001
EO% 0.3 (0–0.9) 0.75 (0.3–2.58) 1.6 (0.3–3.5) 1 (0.18–2.83) < 0.001
NLR 4.28 (3.15–7.72) 4.38 (3.02–6.84) 4.03 (2.99–6.41) 4.82 (2.88–7.93) 0.278
ALB 36.2 (33.55–39.05) 34.75 (31.93–38.48) 34.3 (30.9–38.3) 32.15 (28.3–35.35) < 0.001
UA/CREA 5 (3.98–7.04) 5.24 (4.36–6.58) 5.35 (4.18–6.90) 5.62 (4.32–7.30) 0.476
TG 1.92 (1.37–2.78) 2.16 (1.56–2.79) 1.77 (1.37–2.4) 1.92 (1.44–2.79) 0.032
LDL 2.86 (2.3–3.52) 2.44 (1.89–3.11) 2.24 (1.64–2.77) 1.86 (1.32–2.53) < 0.001
CK 69 (30.5–505.5) 106.5 (41–1786.25) 177 (67–1449) 146.5 (59.75–992) < 0.001
Cumulative proportion     
 No readmission 0.967 0.908 0.890 0.814 0.002
 No need for MV 0.944 0.942 0.92 0.805 0.003
 Survival rate 0.927 0.898 0.881 0.733 < 0.001
  1. Data are presented as n, n (%) for categorical variables and median (interquartile range) for continuous variables
  2. Bold indicates statistical significance
  3. DM dermatomyosis, CADM clinically asymptomatic dermatomyosis, PM polymyosis, OLS overlap syndrome, MDA5 anti-melanoma differentiation-associated gene 5, HB hemoglobin, PLT platelet count, WBC white blood cell count, EO% percentage of eosinophils, NLR neutrophil/lymphocyte ratio, ALB albumin, UA uric acid, CREA creatinine, TG triglycerides, LDL low-density lipoprotein, CK creatine kinase, MV mechanical ventilation